Roy del Rosario, MD
Psychiatry · Lancaster, CANPI 1740381870
Payments from drug & device makers
Across 973 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Lundbeck LLC$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Supernus Pharmaceuticals, Inc.$1K
- plus $6K from 20 others
What the payments were for
- Food & beverage$16,05099%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 153 | $2,244 |
| Alkermes, Inc. | 92 | $1,871 |
| Takeda Pharmaceuticals U.S.A., Inc. | 135 | $1,764 |
| Lundbeck LLC | 104 | $1,627 |
| Otsuka America Pharmaceutical, Inc. | 111 | $1,619 |
| Supernus Pharmaceuticals, Inc. | 79 | $1,394 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 81 | $1,256 |
| Teva Pharmaceuticals USA, Inc. | 40 | $1,185 |
| Johnson & Johnson | 33 | $600 |
| Sunovion Pharmaceuticals Inc. | 31 | $473 |
| Merck | 18 | $314 |
| E.r. Squibb & Sons, L.L.C. | 14 | $286 |
| Avanir Pharmaceuticals, Inc. | 18 | $269 |
| Corium, LLC | 19 | $259 |
| Axsome Therapeutics, Inc. | 7 | $256 |
| Neurocrine Biosciences, Inc. | 9 | $176 |
| Ironshore Pharmaceuticals Inc. | 5 | $109 |
| Idorsia Pharmaceuticals US Inc | 5 | $103 |
| Noven Therapeutics, LLC | 5 | $97 |
| Eisai Inc. | 5 | $70 |
| Almatica Pharma LLC | 2 | $45 |
| Agios Pharmaceuticals, Inc. | 1 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Livanova USA, Inc. | 1 | $28 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$909
- AUSTEDO$363
- REXULTI$125
- Auvelity$125
- TRINTELLIX$110
How this compares
$16,167 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 259 | $406,823 |
| VraylarCariprazine Hcl | 120 | $209,051 |
| TrintellixVortioxetine Hydrobromide | 184 | $110,923 |
| Lurasidone Hcl | 236 | $109,861 |
| CaplytaLumateperone Tosylate | 53 | $98,466 |
| BelsomraSuvorexant | 109 | $53,911 |
| FanaptIloperidone | 30 | $41,480 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $39,969 |
| Invega SustennaPaliperidone Palmitate | 12 | $37,460 |
| AuvelityDextromethorphan Hbr/Bupropion | 37 | $35,678 |
| FetzimaLevomilnacipran Hcl | 60 | $35,596 |
| VyvanseLisdexamfetamine Dimesylate | 68 | $34,074 |
| Aripiprazole | 264 | $24,541 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $23,838 |
| Duloxetine Hcl | 721 | $15,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,619 | $406,823259 claims |
| AbbVieVraylar, Fetzima | $2,244 | $244,647180 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,764 | $144,997252 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,256 | $98,46653 claims |
| MerckBelsomra | $314 | $53,911109 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $40 | $41,48030 claims |
| Alkermes, Inc.Lybalvi | $1,871 | $39,96922 claims |
| Johnson & JohnsonInvega Sustenna | $600 | $37,46012 claims |
| Axsome Therapeutics, Inc.Auvelity | $256 | $35,67837 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $269 | $23,83816 claims |
| Eisai Inc.Dayvigo | $70 | $6,88114 claims |
| Corium, LLCAzstarys | $259 | $6,03615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Lancaster
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.